MRK.DE
$104.05-3.30 (-3.07%)
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs...
Recent News
How The Investment Story For Merck KGaA (XTRA:MRK) Is Quietly Shifting On Cautious Targets
A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125, has put fresh focus on how Merck KGaA is being framed right now. These moves line up with a mix of more cautious voices trimming targets and at least one bank still seeing room for upside while adjusting expectations. Read on to see how to interpret these shifts and keep track of the story as it develops. Analyst Price Targets don't always capture the full story...
Analysis-TrumpRx lists many medicines at prices higher than paid in UK
President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Assessing Merck KGaA (XTRA:MRK) Valuation After Recent Share Price Weakness
Merck KGaA stock overview after recent performance Merck KGaA (XTRA:MRK) has drawn fresh attention after a period of weaker share performance, including a 2.2% one-day decline and double-digit negative returns over the past month and past 3 months. See our latest analysis for Merck KGaA. At a share price of €110.75, Merck KGaA has seen momentum fade recently, with weaker 7 day and 30 day share price returns feeding into a year to date share price return of an 8.7% decline and a 1 year total...
Germany’s Merck KGaA Expects Currency Headwinds to Weigh on Earnings
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
Health Care Roundup: Market Talk
Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.